Advertisement

Interferons: therapy for cancer

  • David Goldstein
  • Robert Jones
  • Richard V. Smalley
  • Ernest C. Borden
Chapter

Abstract

Isaacs and Lindemann, in England, first characterized interferon (IFN) in 1957 and coined the word to signify a protein, elaborated by virus-infected cells, that functions to prevent their infection by a second virus [107]. However, difficulties with chemical isolation and characterization led to great skepticism about the molecule’s existence; indeed, “the scientific community dubbed the discovery ‘imaginon’” [187].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Adams F, Quesada JR, Gutterman JU. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. J Am Med Assoc 1984; 252: 938–41.Google Scholar
  2. 2.
    Aderka D, Levo Y, Ramot B. Reduced production of tumor necrosis factor (TNF) by mononuclear cells of hairy cell leukemia patients and improvement following leukemia therapy. Cancer 1987; 60: 2208–12.PubMedGoogle Scholar
  3. 3.
    Aderka D, Michalevicz R, Daniel Y, et al. Recombinant interferon alpha-C for advanced hairy cell leukemia. Cancer 1988; 61: 2207–13.PubMedGoogle Scholar
  4. 4.
    Ahre A, Bjorkholm M, Mellstedt H et al. Human leuko- cyte interferon and intermittent high dose melphalanprednisone administration in the treatment of multiple myeloma. A randomized clinical trial from the myeloma group of central Sweden. Cancer Treat Rep 1984; 68: 1331–8.PubMedGoogle Scholar
  5. 5.
    Ajani J, Rios AH, Ende K et al. Phase I and II studies of the combination of recombinant human interferon-alpha and 5-fluorouracil in patients with advanced colorectal carcinoma. J Biol Resp Modif 1989; 8: 14–46.Google Scholar
  6. 6.
    Alimena G, Morra E, Lazzarino M et al. Interferon alpha- 2b as therapy for Ph I-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood 1988; 72: 642–7.PubMedGoogle Scholar
  7. 7.
    Allan NC, Richards SM, Shepherd PCA. On behalf of the UK Medical Research Council’s Working Parties for Therapeutic Trials in Adult Leukaemia–UK Medical Research Council randomized multicentre trial of interferon alpha N1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392–97.PubMedGoogle Scholar
  8. 8.
    Allen MJ, Vaughan M, Webb A et al. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study. Br J Cancer 2000; 83: 980–5.PubMedCentralPubMedGoogle Scholar
  9. 9.
    Andersen J, Smalley RV. Interferon alfa plus chemother- apy for non-Hodgkin’s lymphoma: five-year follow up. N Engl J Med 1993; 329: 1821–2.PubMedGoogle Scholar
  10. 10.
    Armitage JO, Coiffier B. Activity of interferon alpha in relapsed patients with diffuse large B-cell and peripheral T-cell non-Hodgkin’s lymphoma. Ann Oncol 2000; 11: 359–61.PubMedGoogle Scholar
  11. 11.
    Aviles A, Cleto S, Huerta-Guzman J, Neri N. Interferon alfa 2b as maintenance therapy in poor risk diffuse large B-cell lymphoma in complete remission after intensive CHOP-BLEO regimens Eur J Haematol 2001; 66: 94–9.Google Scholar
  12. 12.
    Bartsch HH, Pfizenmaier K, Hanusch A et al. Sequential therapy with recombinant interferons gamma and alpha in patients with unfavorable prognosis of chronic myelocytic leukemia: clinical responsiveness to recombinant IFN-a correlates with the degree of receptor down-regulation. Int J Cancer 1989; 43: 235–40.PubMedGoogle Scholar
  13. 13.
    Basham TY, Kaminski MS, Ketamura K et al. Synergistic antitumor effect of interferon and anti-idiotype monoclonal antibody in murine lymphoma. J Imunnol 1986; 137: 3019.Google Scholar
  14. 14.
    Bergsagel DE, Haas RH, Messner HA. Interferon alfa-2b in the treatment of chronic granulocytic leukemia. Invest New Drugs 1987; 5: 9–17.Google Scholar
  15. 15.
    Billard C, Diez RA, Ferbus D et al. Lack of in vivo down-regulation of interferon alpha receptors in non-Hodgkin lymphoma cells from patients unresponsive to interferon-alpha therapy. J Interf Res 1989; 9 (Suppl. 2): S202.Google Scholar
  16. 16.
    Billard C, Sigaux F, Castaigne S et al. Treatment of hairy cell leukemia with recombinant alpha interferon: II. In vivo down-regulation of alpha interferon receptors on tumor cells. Blood 1986; 67: 821–6.PubMedGoogle Scholar
  17. 17.
    Bjorkstrand B, Svensson H, Goldschmidt H et al. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2001; 27: 511–5.PubMedGoogle Scholar
  18. 18.
    Blade J, San Miguel JF, Escudero ML et al. Maintenance treatment with interferon alpha-2b in multiple myeloma; a prospective randomised study from PETHEMA. Leukemia 1998; 12: 1144–8.PubMedGoogle Scholar
  19. 19.
    Borden E. Interferons, rationale for clinical trials in neoplastic disease. Ann Intern Med 1979; 91: 472–9.PubMedGoogle Scholar
  20. 20.
    Borden EC, Holland JF, Dao TL et al. Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society Phase II trial. Ann Intern Med 1982; 97: 1–6.PubMedGoogle Scholar
  21. 21.
    Browman GP, Bergsagel D, Sicheri D, et al. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1995; 13: 2354–60.PubMedGoogle Scholar
  22. 22.
    Bunn PA Jr, Ihde DC, Foon KA. The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas. Cancer 1989; 57: 1689–95.Google Scholar
  23. 23.
    Bunn PA, Foon KA, Ihde DC et al. Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med 1984; 101: 484–7.PubMedGoogle Scholar
  24. 24.
    Carrel S, Schmidt-Kessen A, Giuffre L. Recombinant interferon-gamma can induce the expression of HLA-DR and DC- or DR-negative melanoma cells and enhance the expression of HLA-ABC and tumor-associated antigens. Eur J Immunol 1985; 15: 118–23.PubMedGoogle Scholar
  25. 25.
    Cascinelli N. Evaluation of efficacy of adjuvant rIFNa 2A in melanoma patients with regional node metastases. Proc Am Soc Clin Oncol 1995; 14: 1296A.Google Scholar
  26. 26.
    Case DC Jr, Sonneborn HL, Paul SD et al. Phase II study of rDNA alpha-2 interferon (Intron A) in patients with multiple myeloma utilizing an escalating induction phase. Cancer Treat Rep 1986; 70: 1251–4.PubMedGoogle Scholar
  27. 27.
    Cheson BD, Sorensen JM, Vena DA et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients J Clin Oncol 1998; 16: 3007–15.Google Scholar
  28. 28.
    Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal cell carcinoma after non-myeloablative allogeneic peripheral blood stem cell transplantation. N Engl J Med 2000; 343 750–8.PubMedGoogle Scholar
  29. 29.
    Chisesi T, Capnist G, Vespignani M et al. Interferon alfa-2b and chlorambucil in the treatment of non-Hodgkin’s lymphoma. Invest New Drugs 1987; 5: 535–40.Google Scholar
  30. 30.
    Clark RH, Dimitrov NV, Axelson JA et al. Leukocyte interferon as a possible biological response modifier in lymphoproliferative disorders resistant to standard therapy. J Biol Resp Mod 1984; 3: 613–19.Google Scholar
  31. 31.
    Clark RH, Dimitrov NV, Axelson JA. A phase II trial of intermittent leukocyte interferon and high dose chlorambucil in the treatment of non-Hodgkin’s lymphoma resistant to conventional therapy. Am J Clin Oncol 1989; 12: 75–7.PubMedGoogle Scholar
  32. 32.
    Clemens M. Interferons and oncogenes. Nature 1985; 313: 531–2.PubMedGoogle Scholar
  33. 33.
    Cole BF, Gelber RD, Kirkwood JM et al. Quality-of-lifeadjusted survival analysis of interferon alpha-2b adjuvant treatment of high risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1996; 14: 2666.Google Scholar
  34. 34.
    Cole BF, Solal-Celigny P, Gelber RD, Lepage E. Qualityof-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making. J Clin Oncol 1998; 16: 2339–44.PubMedGoogle Scholar
  35. 35.
    Cooper MR. Interferons in the management of multiple myeloma. Semin Oncol 1988; 15: 21–5.PubMedGoogle Scholar
  36. 36.
    Cooper MR, Fefer A, Thompson J et al. Alpha-2-interferon/melphalan/prednisolone in previously untreated patients with multiple myeloma: a phase I-II trial. Cancer Treat Rep 1986; 70: 473–6.PubMedGoogle Scholar
  37. 37.
    Coppin C, Porzsolt F, Kumpf J et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2000; 3: CD001425.Google Scholar
  38. 38.
    Costanzi JJ, Cooper MR, Scarffe JH et al. Phase II study of recombinant alpha 2 interferon in resistant multiple myeloma. J Clin Oncol 1985; 3: 654–9.PubMedGoogle Scholar
  39. 39.
    Costanzi JJ, Pollard RB. The use of interferon in the treatment of multiple myeloma. Semin Oncol 1987; 14: 24–8.PubMedGoogle Scholar
  40. 40.
    Creagan ET, Ahmann DL, Green SJ et al. Phase II study of recombinant leukocyte A interferon (RIFN-alpha-A) in disseminated malignant melanoma. Cancer 1984; 54: 2844–9.PubMedGoogle Scholar
  41. 41.
    Cunningham D, Powles R, Malpas J et al. A randomised trial of maintenance interferon following high-dose chemotherapy in multiple myeloma; long-term follow-up results. Br J Haematol 1998; 102, 495–502PubMedGoogle Scholar
  42. 41a.
    Davis TA, Maloney DG, Grillo-López AJ. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma with Rituximab and interferon-2a. Clin Cancer Res 2000; 6: 2644–52.PubMedGoogle Scholar
  43. 42.
    DeMaeyer-Guignard J, DeMaeyer E. Immunomodulation by interferons: recent developments. In: I. Gresser, ed. Interferon, Vol. 6. New York: Academic Press, 1985: 69–86.Google Scholar
  44. 43.
    Dewit R, Boucher CAB, Veenhof KHN et al. Clinical and virological effects of high-dose recombinant interferon alpha in disseminated AIDS-related Kaposi’s sarcoma. Lancet 1988; 2: 1214–17.Google Scholar
  45. 44.
    Dinney CPN, Bielenberg DR, Reich R et al. Inhibition of basic fibrobroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon alpha administration. Cancer Res 1998; 58: 808.PubMedGoogle Scholar
  46. 45.
    Druker BJ, Talpaz M, Resta RN et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase inGoogle Scholar
  47. chronic myeloid leukemia N Engl J Med 2001; 344:1031–7.Google Scholar
  48. 46.
    Dutcher JP, Logan T, Gordon M et al. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin Cancer Res 2000; 6: 3442–50.PubMedGoogle Scholar
  49. 47.
    Edwards BS, Hawkins MJ, Borden EC. Comparative in vivo and in vitro activation of human NK cells by two recombinant interferons alpha differing in anti-viral activity. Cancer Res 1984; 44: 3135–9.PubMedGoogle Scholar
  50. 48.
    Edwards BS, Merritt JA, Fuhlbrigge RL et al. Low doses of interferon alpha result in more effective clinical natural killer cell activation. J Clin Invest 1985; 75: 1908–13.PubMedCentralPubMedGoogle Scholar
  51. 49.
    Einhorn N, Cantell K, Einhorn S et al. Human leukocyte interferon. Am J Clin Oncol 1982; 5: 167–72.PubMedGoogle Scholar
  52. 50.
    Einhorn S, Ahre A, Blomgren H et al. Interferon and natural killer activity in multiple myeloma. Lack of correlation between interferon-induced enhancement of natural killer activity and clinical response to human interferon-alpha. Int J Cancer 1982; 30: 167–72.PubMedGoogle Scholar
  53. 51.
    Einhorn S, Blomgren H, Strander H. Interferon and spontaneous cytotoxicity in man. Acta Med Scand 1978; 204: 477–83.PubMedGoogle Scholar
  54. 52.
    Eisen T, Boschoff C, Mak I et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000; 82: 812–17.PubMedCentralPubMedGoogle Scholar
  55. 53.
    Elhilali MM, Gleave M, Fradet Y et al. Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. The Canadian Urologic Oncology Group. BJU Int 2000; 86: 613–8.PubMedGoogle Scholar
  56. 54.
    Eton O, Legha S, Bedikian A et al. Phase III randomized trial of cisplatin vinblastine and dacarbazine (CVD) plus interleukin-2 (IL2) and interferon-alpha-2b (INF) versus CVD in patients with metastatic melanoma. Proc Am Soc Clin Oncol 2000; 19: 2174.Google Scholar
  57. 55.
    Evans LM, Itri LM, Campion M et al. Alfa interferon 2a in the treatment of AIDS related Kaposi’s sarcoma. J Interf Res 1989; 9: S207.Google Scholar
  58. 56.
    Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992; 326: 1456.PubMedGoogle Scholar
  59. 57.
    Falkson CI, Ibrahim J, Kirkwood J, Blum R. A randomized phase III trial of Dacarbazine (DTIC) versus DTIC + interferon alfa 2b (ifn) versus DTIC + Tamoxifen (TMX) versus DTIC + IFN + TMX in metastatic malignant melanoma: an ECOG Trial. Proc Am Soc Clin Oncol 1996; 15: 435.Google Scholar
  60. 58.
    Falkson CI, Ibrahim J, Kirkwood JM et al. Phase III trial of dacarbazine with tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998; 16: 1743–51.PubMedGoogle Scholar
  61. 59.
    Faltynek CR, Princler GL, Rossio JL et al. Relationship of the clinical response and binding of recombinant interferon alpha in patients with lymphoproliferative diseases. Blood 1986; 67: 1077–82.PubMedGoogle Scholar
  62. 60.
    Farkilla M, Ilvanainen M, Roine R et al. Neurotoxic and other side effects of high-dose interferon in amyotrophic lateral sclerosis. Acta Neurol Scand 1984; 69: 42–6.Google Scholar
  63. 61.
    Figlin RA, deKernion JB, Maldazys J, Sarna G. Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination: a phase III trial. Cancer Treat Rep 1985; 69: 263–7.PubMedGoogle Scholar
  64. a. Richard IF, Dana BW, LeBlanc M. Interferon alfa consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin’s lymphoma: results of the Southwest On-Google Scholar
  65. cology Group Randomized Phase III Study 8809. J Clin Oncol 2000; 18: 2010–20.Google Scholar
  66. 62.
    Flanigan C, Blumnetsein BA, Salomon S et al. Cytoreduction nephrectomy in metastatic renal cancer: the results of South west Oncology Group trial 8949. Proc Am Soc Clin Oncol 2000; 19: 2a: 2000.Google Scholar
  67. 63.
    Foon KA, Bottino GC, Abrams PG et al. Phase II trial of recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia. Am J Med 1985; 78: 216.PubMedGoogle Scholar
  68. 64.
    Foon KA, Sherwin SA, Abrams PG et al. Treatment of advanced non-Hodgkin’s lymphoma with recombinant leukocyte A interferon. N Engl J Med 1984; 311: 1148–52.PubMedGoogle Scholar
  69. 65.
    Ford RJ, Kwok D, Quesada J et al. Production of B cell growth factor(s) by neoplastic B cells from hairy cell leukemia patients. Blood 1986; 67: 573–7.PubMedGoogle Scholar
  70. 66.
    Fossa~ S, Martinelli G, Otto U et al. Recombinant interferon-alpha-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-centre phase III study. Ann Oncol 1992; 3: 301–5.PubMedGoogle Scholar
  71. 67.
    Frank M, Klose KJ, Wied M et al. Combination therapy with octreotride and alpha-interferon: effect on tumour growth in metastatic endocrine gastropancreatic tumours. Am J Gastroenerol 1999; 94: 1381–7.Google Scholar
  72. 68.
    Gams R, Gordon D, Guaspari A et al. Phase II trial of human polyclonal lymphoblastoid interferon in the management of malignant lymphomas. Proc Am Soc Clin Oncol 1984; 3: 65 (abstract).Google Scholar
  73. 69.
    Gastl G, Aulitzky W, Liter E et al. Alpha interferon induces remission in hairy cell leukemia without enhancement of natural killing. Blut 1986; 52: 273–9.PubMedGoogle Scholar
  74. 70.
    Gastl G, Aulitzky W, Tilg H et al. A biological approach to optimize interferon treatment in hairy cell leukemia. Immunobiology 1986; 172: 262–8.PubMedGoogle Scholar
  75. 71.
    Gastl G, Denz H, Abbrederis C et al. Treatment with low dose human recombinant interferon-alpha-2 ARG induces complete remission in patients with hairy cell leukemia. Onkologie 1985; 8: 143–4.PubMedGoogle Scholar
  76. 72.
    Gastl G, Werter M, De Pauw B et al. Comparison of clinical efficacy and toxicity of conventional and optimum biological response modifying doses of interferon alpha-2C in the treatment of hairy cell leukemia: a retrospective analysis of 39 patients. Leukemia 1989; 3: 453–60.PubMedGoogle Scholar
  77. 73.
    Gelmann EP, Preble OT, Steis R et al. Human lymphoblastoid interferon treatment of Kaposi’s sarcoma in the acquired immune deficiency syndrome. Am J Med 1985; 78: 737–41.PubMedGoogle Scholar
  78. 74.
    Giacomini P, Aguzzi A, Pestka S. Modulation by recombinant DNA leukocyte (a) and fibroblast (b) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells. J Immunol 1984; 133: 1649–55.PubMedGoogle Scholar
  79. 75.
    Giacomini P, Imberti L, Aguzzi A et al. Immunochemical analysis of the modulation of human melanoma-associated antigens by DNA recombinant immune interferon. J Immunol 1985; 135: 2887–94.PubMedGoogle Scholar
  80. 76.
    Gibson J, Cameron K, Gallagher K et al. Clinical response of hairy cell leukaemia to interferon-a: results of an Australian study. Med J Aust 1988; 149: 293–6.PubMedGoogle Scholar
  81. 77.
    Gibson J, Gallagher K, Cameron K et al. Peripheral blood lymphocyte subsets and natural killer cell number and function during a-interferon treatment for hairy cell leukemia. Aust NZ J Med 1988; 18: 897–8.Google Scholar
  82. 78.
    Gill PS, Harrington W Jr, Kaplan MH et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995; 332: 1744–8.PubMedGoogle Scholar
  83. 79.
    Gisslinger H, Ludwig H, Linkesch W et al. Long-term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet 1989; 1: 634–7.PubMedGoogle Scholar
  84. 80.
    Gleave ME, Elhilali M, Fradet Y et al. Interferon gamma-1b compared with placebo in metastatic renal cell carcinoma. N Engl J Med 1998; 338: 1265–71.PubMedGoogle Scholar
  85. 81.
    Goldstein D, Guadagni F, Greiner J et al. Clinical and biological effects of intraperitoneal interferon gamma in a phase 1A/b trial in ovarian carcinoma. J Interf Res 1989; 9: S115.Google Scholar
  86. 82.
    Goldstein D, Sielaff KM, Storer BE et al. Human biologic response modification in the absence of serum concentrations: a comparative trial of subcutaneous and intravenous interferon beta ser. J Natl Cancer Inst 1989; 81: 1061–8.PubMedGoogle Scholar
  87. 83.
    Golomb HM, Fefer A, Golde DW. Report of a multiinstitutional study of 193 patients with hairy cell leukemia treated with interferon-alfa 2b. Semin Oncol 1988; 15: 7–9.PubMedGoogle Scholar
  88. 84.
    Golomb HM, Jacobs A, Fefer A et al. Alpha-2 interferon therapy of hairy cell leukemia: a multi-center study of 64 patients. J Clin Oncol 1986; 4: 900–5.PubMedGoogle Scholar
  89. 85.
    Golomb HM, Ratain MJ, Fefer A et al. Randomized study of the duration of treatment with interferon alfa-2B in patients with hairy cell leukemia. J Natl Cancer Inst 1988; 80: 369–73.PubMedGoogle Scholar
  90. 86.
    Gore ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–80.Google Scholar
  91. 87.
    Greiner JW, Hand PH, Naguchi P et al. Enhanced expression of surface tumor associated antigen on human breast and colon tumor cells after recombinant human leukocyte a-interferon treatment. Cancer Res 1984; 44: 3208–11.PubMedGoogle Scholar
  92. 88.
    Gresser I. How does interferon inhibit tumor growth? In: Gresser I, ed. Interferon, Vol. 6. New York: Academic Press, 1985: 93–126.Google Scholar
  93. 89.
    Grillo-Lopez AJ, White CA, Dallaire BK et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol 2000; 1: 1–9.PubMedGoogle Scholar
  94. 90.
    Grob JJ, Dreno B, de la Salmoniere P et al. Randomised trial of interferon alpha-2a as adjuvant treatment in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Co-operative Group on Melanoma. Lancet 1998; 351: 1905–10.PubMedGoogle Scholar
  95. 91.
    Groopman J, Gottlieb M, Goodman J et al. Recombinant alpha-2 interferon therapy for Kaposi’s sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 100: 671–6.PubMedGoogle Scholar
  96. 92.
    Guadagni F, Schlom J, Johnston W et al. Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. J Natl Cancer Inst 1989; 81: 502–12.PubMedGoogle Scholar
  97. 93.
    Gugliotta L, Bagnara GP, Catani L et al. In vivo and in vitro inhibitory effect of alpha interferon on megakaryocyte colony growth in essential thrombocythaemia. Br J Hematol 1989; 71: 177–81.Google Scholar
  98. 94.
    Guilhot F, Chastang C, Mihallet M et al. Interferon alpha 2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997; 337: 223–9.PubMedGoogle Scholar
  99. 95.
    Gutterman JU, Blumenschein AR, Alexanian R et al. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann Intern Med 1980; 93: 399–406.PubMedGoogle Scholar
  100. 96.
    Hagenbeek A, Carde P, Meerwaldt JH et al. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin’s lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1998; 16: 41–7.PubMedGoogle Scholar
  101. 97.
    Hänninen EL, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive single institution patients. J Urol 1996; 155: 19–25.Google Scholar
  102. 98.
    Hehlmann R, Anger B, Messerer D et al. Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha. Blut 1988; 56: 87–91.PubMedGoogle Scholar
  103. 99.
    Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of interferon alpha with Busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994; 84: 4064–77.PubMedGoogle Scholar
  104. 100.
    Herberman RB, Ortaldo JR. Natural killer cells: their role in defenses against disease. Science 1981; 214: 24–30.PubMedGoogle Scholar
  105. 101.
    Heyns AP, Eldor A, Vlodavsky I et al. The antiproliferative effect of interferon and the mitogenic activity of growth factors are independent cell cycle events. Exp Cell Res 1985; 161: 297.PubMedGoogle Scholar
  106. 102.
    Hill M, Norman A, Cunningham D et al. Royal Marsden phase III trial of fluorouracil with or without interferon alfa 2b in advanced colorectal cancer. J Clin Oncol 1995; 13: 1297–302.PubMedGoogle Scholar
  107. 103.
    Holtl L, Reiser C, Papesch C et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 1999; 161: 777–82.PubMedGoogle Scholar
  108. 104.
    Horning SJ, Merigan TL, Krown SE et al. Human interferon alpha in malignant lymphoma and Hodgkin’s disease. Cancer 1985; 56: 1305–10.PubMedGoogle Scholar
  109. 105.
    Huber C, Batchelor JR, Fuchs D et al. Immune response-associated production of neopterin. J Exp Med 1984; 160: 310–16.PubMedGoogle Scholar
  110. 106.
    Huncharek M, Caubet JF, McGarry R. Single agent DTIC versus combination therapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001; 11: 75–81.PubMedGoogle Scholar
  111. 107.
    Isaacs H, Lindemann J. Virus interference. 1. The interferon. Proc R Soc Oncol Biol 1957; 147: 257–62.Google Scholar
  112. 108.
    Itri LM, Campion M, Dennin RA et al. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa 2a by intramuscular injection. Cancer 1987; 59: 668–74.PubMedGoogle Scholar
  113. 109.
    Johnston JB, Eisenhauer E, Wainman N et al. Long-term outcome following treatment of hairy cell leukemia with pentostatin; a National Cancer Institute of Canada study. Semin Oncol 2000; 27 (Suppl. 5): 32–6.PubMedGoogle Scholar
  114. 110.
    Jonasch E, Haluska FG. Interferon in oncological practice; review of interferon biology, clinical applications, and toxicities. Oncologist 2001; 6: 34–55.PubMedGoogle Scholar
  115. 111.
    Joshua DE, Penny R, Matthews JP et al. Australian leukemia study group myeloma II: a randomised study of intensive combination chemotherapy with or without interferon in patients with myeloma. Br J Haematol 1997; 97: 38–45.PubMedGoogle Scholar
  116. 112.
    Jumbou O, N’Guyen JM, Tessier MH, Legoux B, Dreno B. Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa. Br J Dermatol 1999; 140: 427–31.PubMedGoogle Scholar
  117. 113.
    Kaban LB, Mulliken JB, Ezekowiitz RA et al. Antiangiogenic therapy of a recurrent giant cell tumour of the mandible with interferon alpha-2a. Pediatrics 1999; 103: 1145.PubMedGoogle Scholar
  118. 114.
    Kantarjian HM, O’Brien S, Smith TL et al. Treatment of Philadelphia chromosome-positive early chronic phase myelogenous leukemias with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol 1999; 17: 284–93.PubMedGoogle Scholar
  119. 115.
    Kantarjian HM, Smith TL, O’Brien S et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon alpha therapy. Ann Intern Med 1995; 122: 254–61.PubMedGoogle Scholar
  120. 115a.
    Kantarjian HM, Keating MJ, Estey EH et al. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha low-dose cytarabine. J Clin Oncol 19982; 10: 772–8.Google Scholar
  121. 116.
    Keiholz U, Goey SH, Punt CJ et al. Interferon alpha-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organisation for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997; 15: 2579–88.Google Scholar
  122. 117.
    Kirchner H. Interferons, a group of multiple lymphokines. Semin Immunopathol 1984; 7: 347–74.Google Scholar
  123. 118.
    Kirkwood JM, Ernstoff MS, Davis CA et al. Comparison of intramuscular and intravenous recombinant a-2 interferon in melanoma and other cancers. Ann Intern Med 1985; 103: 32–6.PubMedGoogle Scholar
  124. 119.
    Kirkwood JM, Ibrahim JG, Sondak VK et al. High-and low-dose interferon alpha-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18: 2444–58.PubMedGoogle Scholar
  125. 120.
    Kirkwood JM, Ibrahim JG, Sosman JA et al. High dose interferon alpha-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19: 2370–80.PubMedGoogle Scholar
  126. 121.
    Kirkwood JM, Strawderman MH, Ernsthoff MS et al. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous lymphoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7–17.PubMedGoogle Scholar
  127. 122.
    Kreitman RJ, Wilson WH, Bergeron K et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy resistant hairy cell leukemia, N Engl J Med 2001; 345: 241–7.PubMedGoogle Scholar
  128. 123.
    Krigel RL, Slywotzky CM, Louiberg M et al. Treatment of epidemic Kaposi’s sarcoma with a combination of interferon-alpha-2b and etoposide. J Biol Resp Modif 1988; 7: 359–64.Google Scholar
  129. 124.
    Krown SE. The role for interferon in the therapy of epidemic Kaposi’s sarcoma. Semin Oncol 1987; 2: 27–33.Google Scholar
  130. 125.
    Kugler A, Stuhler G, Walden P et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000; 6: 332–6.PubMedGoogle Scholar
  131. 126.
    Kurzrock R, Talpaz M, Kantarjian H et al. Therapy of chronic myelogenous leukemia with recombinant interferon-alpha. Blood 1987; 70: 943–7.PubMedGoogle Scholar
  132. 127.
    Kuzel TM, Gilyon K, Springer E et al. Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990; 82: 203–7.PubMedGoogle Scholar
  133. 128.
    Kuzel TM, Roenigk HH, Samuelson E et al. Effectiveness of interferon alpha 2a combined with phototherapy for mycosis fungoides and the Se~zary syndrome. J Clin Oncol 1995; 13: 257.PubMedGoogle Scholar
  134. 129.
    Laszlo J, Huang AT, Brenkman WD et al. Phase I study of pharmacological and immunological effects of human lymphoblastoid interferon given to patients with cancer. Cancer Res 1983; 43: 4458–66.PubMedGoogle Scholar
  135. 130.
    Lazzarino M, Vitalle A, Morra E et al. Interferon alpha-2b as treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosis. Br J Haematol 1989; 72: 173–7.PubMedGoogle Scholar
  136. 131.
    Leavitt RD, Ratanatharathorn V, Ozer H et al. Alfa-2b interferon in the treatment of Hodgkin’s disease and non-Hodgkin’s lymphoma. Semin Oncol 1987; 14 (Suppl. 2): 18–23.PubMedGoogle Scholar
  137. 132.
    Lenhoff S, Hjorth M, Holmberg E et al. Impact on survival of high dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population based study. Blood 2000; 95: 7–11.PubMedGoogle Scholar
  138. 133.
    Liao MJ, Lee N, Dipaola G et al. Distribution of interferon alpha 2 genes in humans. J Interferon Res 1994; 14: 183–5.PubMedGoogle Scholar
  139. 134.
    Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001; 61: 253–70.PubMedGoogle Scholar
  140. 135.
    Lingen MW, Polverini PJ, Bouk NP et al. Retinoic acid and interferon alpha act synergistically as antiangiogenic antitumour agents against human head and neck squamous cell carcinoma. Cancer Res 1998; 58: 5551–8.PubMedGoogle Scholar
  141. 136.
    Lippman SM, Kavanagh JJ, Paredes-Espinoza M et al. 13 Cis-retinoic acid plus interferon alfa 2a: a highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992; 84: 241.PubMedGoogle Scholar
  142. 137.
    Lippman SM, Parkinson DR, Itri LM et al. 13-Cis-retinoic acid plus interferon alfa 2a: effective combination therapy for advanced squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992; 84: 235–40.PubMedGoogle Scholar
  143. 138.
    Lotzova E, Savary CA, Gutterman JU et al. Regulation of natural killer cell cytotoxicity by recombinant leukocyte interferon clone A. J Biol Resp Modif 1983; 2: 482–98.Google Scholar
  144. 139.
    Louie AC, Gallagher JG, Sikora K et al. Followup observations on the effect of human leukocyte interferon in non-Hodgkin’s lymphoma. Blood 1981; 58: 712–18.PubMedGoogle Scholar
  145. 140.
    Lucero MA, Magdalenat H, Friedman WH et al. Comparison of effects of leukocyte and fibroblast interferon on immunological parameters in cancer patients. Eur J Cancer Clin Oncol 1982; 18: 243–51.PubMedGoogle Scholar
  146. 141.
    Ludwig H, Cortelezzi A, Scheithauer W et al. Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial. Eur J Cancer Clin Oncol 1986; 22: 1111–16.PubMedGoogle Scholar
  147. 142.
    Ludwig H, Fritz E. Interferon in multiple myeloma–summary of treatment results and clinical implications. Acta Oncol 2000; 39: 815–21.PubMedGoogle Scholar
  148. 143.
    Maluish AE, Leavitt R, Sherwin S et al. Effects of recombinant interferon-alpha on immune function in cancer patients. J Biol Resp Modif 1984; 2: 470–81.Google Scholar
  149. 144.
    Maluish AE, Ortaldo JR, Conlon J et al. Depression of natural killer cytotoxicity after in vivo administration of recombinant leukocyte interferon. J Immunol 1983; 131: 503–7.PubMedGoogle Scholar
  150. 145.
    Maluish AE, Ortaldo JR, Sherwin SA et al. Changes in immune function in patients receiving natural leukocyte interferon. J Biol Resp Modif 1983; 2: 418–22.Google Scholar
  151. 146.
    Mandelli F, Avvisati G, Amadori S et al. Maintenance treatment with recombinant interferon alpha 2b recombinant in multiple myeloma patients responding to conventional induction chemotherapy. N Engl J Med 1990; 322: 1430–4.PubMedGoogle Scholar
  152. 147.
    Marumo K, Murai M, Hagakawa M et al. Human lymphoblastoid interferon therapy for advanced renal cell carcinoma. Urology 1984; 24: 567–71.PubMedGoogle Scholar
  153. 148.
    Mauss S, Jablonowski H. Efficacy, safety, and tolerance of low-dose, long-term interferon-alpha 2b and zidovudine in early-stage AIDS-associated Kaposi’s sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 10: 157–62.PubMedGoogle Scholar
  154. 149.
    McClay E, Mastrangelo M, Berd D et al. Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer 1992; 50: 553–6.PubMedGoogle Scholar
  155. 150.
    McLaughlin P, Cabanillan F, Hagemeister F et al. CHOPBleo plus interferon for stage IV low-grade lymphoma. Ann Oncol 1993; 4: 205–11.PubMedGoogle Scholar
  156. 151.
    Medical Research Council Renal Cancer Collaborators: Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet 1999; 353: 14–17.Google Scholar
  157. 152.
    Meeker T, Lowder J, Cleary ML et al. Emergence of idiotype variants during treatment of B-cell lymphomas with anti-idiotype antibodies. N Engl J Med 1985; 312: 1658.PubMedGoogle Scholar
  158. 153.
    Meeker TC, Lowder J, Maloney DG et al. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 1985; 65: 1349.PubMedGoogle Scholar
  159. 154.
    Mellstedt H, Ahre A, Bjorkhelm M et al. Interferon therapy in myelomatosis. Lancet 1979; 1: 245–7.PubMedGoogle Scholar
  160. 155.
    Merigan TL, Sikorak K, Breeden JH et al. Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin’s lymphoma. N Engl J Med 1978; 299: 1449–53.PubMedGoogle Scholar
  161. 156.
    Michalevicz R, Revel M. Interferons regulate the in vitro differentiation of multilineage lympho-myeloid stem cells in hairy cell leukemia. Proc Natl Acad Sci USA 1987; 84: 2307–11.PubMedGoogle Scholar
  162. 157.
    Moertel CG, Rubin J, Kvols LK. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte alpha interferon. J Clin Oncol 1989; 7: 865.PubMedGoogle Scholar
  163. 158.
    Motzer RJ, Murphy BA, Bacik J et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18: 2972–80.PubMedGoogle Scholar
  164. 159.
    Motzer RJ, Rakhit A, Ginsberg M et al. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. J Clin Oncol 2001; 19: 1312–19.PubMedGoogle Scholar
  165. 160.
    Motzer RJ, Rakhit A, Thompson JA et al. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res 2001; 21: 257–63.PubMedGoogle Scholar
  166. 161.
    Muss HB, Welander C, Caponera M et al. Interferon and doxorubicin in renal cell carcinoma. Cancer Treat Rep 1985; 69: 721–2.PubMedGoogle Scholar
  167. 162.
    Musselman D, Lawson DH, Gumnick JF et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344: 961–6Google Scholar
  168. 163.
    Neefe JR, Sullivan JE, Ayoob M et al. Augmented immunity in cancer patients treated with alpha-interferon. Cancer Res 1985; 45: 874–8.PubMedGoogle Scholar
  169. 164.
    Negrier S, Escudier B, Lasset C et al: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998; 338: 1273–8.Google Scholar
  170. 165.
    Neidhart JA, Anderson SA, Harris JE et al. Vinblastine fails to improve response of renal cancer to interferon alfa-n1 (Wellferon); high response rate in patients with pulmonary metastases. J Clin Oncol 1991; 9: 832–7.PubMedGoogle Scholar
  171. 166.
    Neuman HA, Fauser AA. Effect of interferon on pluripotent hemopoietic progenitors (CFU-GEMM) derived from human bone marrow. Exp Hematol 1982; 10: 587.Google Scholar
  172. 167.
    Niederle N, Kloke O, May D et al. Treatment of chronic myelogenous leukemia with recombinant interferon alfa-2b. Invest New Drugs 1987; 5: 19–25.Google Scholar
  173. 168.
    Nielsen B, Hokland M, Justesen J et al. Immunological recovery and dose evaluation in IFN-a treatment of hairy cell leukemia: analysis of leukocyte differentiation antigens, NK and 2’,5’-oligoadenylate synthetase activity. Eur J Haematol 1989; 42: 50–9.PubMedGoogle Scholar
  174. 169.
    Nordic Myeloma Study Group. Interferon-a 2b added to melphalan-prednisone for initial and maintenance ther-Google Scholar
  175. apy in multiple myeloma. Ann Intern Med 1996; 124: 212–22.Google Scholar
  176. 170.
    Oberg K, Alm G, Magnusson A et al. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing IFN antibodies and possible loss of antitumor activity. J Natl Cancer Inst 1989; 81: 531.PubMedGoogle Scholar
  177. 171.
    O’Connell MJ, Colgan JP, Oken MM et al. Clinical trials of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin’s lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group Pilot Study. J Clin Oncol 1986; 4: 128–36.PubMedGoogle Scholar
  178. 172.
    Ohnishi K, Ohno R, Tomonaga M et al. A randomized trial comparing interferon-a with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995; 86: 906–16.PubMedGoogle Scholar
  179. 173.
    Ohno R, Kimura K. Treatment of multiple myeloma with recombinant interferon alfa-2a. Cancer 1986; 57: 1685–8.PubMedGoogle Scholar
  180. 174.
    Oken MM, Kyle RA, Kay NE et al. A phase II trial of interferon alpha-2 (rIFN-a2) in the treatment of resistant multiple myeloma (MM). Proc Am Soc Clin Oncol 1985; 4: 215 (abstract).Google Scholar
  181. 175.
    Oken MM, Leong T, Lenhard RE Jr et al. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III ECOG EST 9486. Cancer 1999; 15: 957–63.Google Scholar
  182. 176.
    Oladipupo-Williams CK, Svet-Moldavskaya I, Vilcek J. Inhibitory effects of human leukocyte and fibroblast inter-ferons on normal and chronic myelogenous leukemic granulocytic progenitor cells. Oncology 1981; 38: 356–60.Google Scholar
  183. 177.
    Oldham RK. Biologicals and biologic response modifiers. The fourth modality of cancer therapy. Cancer Treat Rep 1984; 68: 221–32.Google Scholar
  184. 178.
    Olsen E, Duvic M, Frankel A et al. Pivotal phase III trial of two dose levels of denileukin difitox treatment of cutaneous T-cell lymphoma J Clin Oncol 2001; 19: 376–88.Google Scholar
  185. 179.
    Olsen EA, Rosen ST, Vollmer RT et al. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol 1989; 20: 395–407.PubMedGoogle Scholar
  186. 180.
    Opravil M, Hirschel B, Bucher HC, Luthy R. Related articles. A randomized trial of interferon-alpha2a and zidovudine versus bleomycin and zidovudine for AIDS-related Kaposi’s sarcoma. Swiss HIV Cohort Study. Int J STD AIDS. 1999; 10: 369–75.PubMedGoogle Scholar
  187. 181.
    Osserman ET, Sherman WF, Alexanian R et al. Preliminary results of the American Cancer Society-sponsored trial of human leukocyte interferon in multiple myeloma. Proc Am Assoc Cancer Res 1980; 21: 161 (abstract).Google Scholar
  188. 182.
    OWsterborg A, Björkholm M, Bjöeman M et al. Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III. A randomized study from the Myeloma Group of Central Sweden. Blood 1993; 81:1428–34.Google Scholar
  189. 183.
    Ozer H. Biotherapy of chronic myelogenous leukemia with interferon. Semin Oncol 1988; 15 (Suppl. 5): 14–20.PubMedGoogle Scholar
  190. 184.
    Ozer H, Anderson JR, Peterson BA et al. Combination trial of subcutaneous interferon alfa-2b and oral cyclophosphamide in favorable histology, non-Hodgkin’s lymphoma. Invest New Drugs 1987; 5: 527–3.Google Scholar
  191. 185.
    Ozer H, Golomb HM, Zimmerman H et al. Cost benefit analysis of interferon alfa 2-b in the treatment of hairy cell leukemia. J Natl Cancer Inst 1989; 8: 594–602.Google Scholar
  192. 186.
    Pagannelli KA, Evans SS, Hant T et al. B cell growth factor-induced proliferation of hairy cell lymphocytes and inhibition by type I interferon in vitro. Blood 1986; 67: 937–42.Google Scholar
  193. 187.
    Panem S. The Interferon Crusade. Washington, DC, Brookings Institute, 1985.Google Scholar
  194. 188.
    Pangalis GA, Griva E. Recombinant alfa-2b-interferon therapy in untreated, stages A and B chronic lymphocytic leukemia. Cancer 1988; 61: 869–72.PubMedGoogle Scholar
  195. 189.
    Paulnock DM, Borden EC. Modulation of immune functions by interferons. In: Immunity to Cancer, New York: Academic Press, 1985: 545–59.Google Scholar
  196. 190.
    Peest D, Deicher H, Coldewey R et al. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. Eur J Cancer 1995; 31A: 146–51.Google Scholar
  197. 191.
    Pehamberger H, Soyer HP, Steiner A et al. Adjuvant interferon alpha-2a in resected primary stage II cutaneous melanoma. J Clin Oncol 1998; 16: 1425–9.PubMedGoogle Scholar
  198. 192.
    Peterson BA, Petroni G, Oken M, Ozer H. Cyclophosphamide vs. cyclophosphamide plus interferon alfa-2b in follicular low grade lymphomas. Proc Am Soc Clin Oncol 1997; 16: 41–7.Google Scholar
  199. 193.
    Pfeffer LM, Dinarello CA, Herberman RB et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998; 58: 2489–99.PubMedGoogle Scholar
  200. 194.
    Pitha P. For the Nomenclature Committee of the International Society for Interferon Research. Nomenclature of the human interferon genes. J Int Res 1993; 13: 443–4.Google Scholar
  201. 195.
    Pizzocaro G, Piva L, Colavita M et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001; 19: 425–31.PubMedGoogle Scholar
  202. 196.
    Poiesz BJ, Ruscetti FW, Gazdar AF et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77: 7415–19.PubMedGoogle Scholar
  203. 197.
    Pope GR, Hadam MR, Eisenburg J et al. Kinetics of natural cytotoxicity in patients treated with human fibroblast interferon. Cancer Immunol Immunother 1981; 11: 1–6.Google Scholar
  204. 198.
    Porzsolt F. Adjuvant therapy of renal cell cancer with interferon alfa-2A. Proc Am Soc Clin Oncol 1992; 11: 202.Google Scholar
  205. 199.
    Pyrhonen S, Salminen E, Ruutu M et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17: 2859–67.PubMedGoogle Scholar
  206. 200.
    Quesada JR, Alexanian R, Hawkins Metal. Treatment of multiple myeloma with recombinant alpha interferon. Blood 1986; 67: 275–8.PubMedGoogle Scholar
  207. 201.
    Quesada JR, Alexanian R, Kurzrock R et al. Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, Waldenstrom’s macroglobulinemia. Am J Hematol 1988; 29: 1–4.PubMedGoogle Scholar
  208. 202.
    Quesada JR, Hersh EM, Manning J et al. Treatment of hairy cell leukemia with recombinant a-interferon. Blood 1986; 68: 493–7.PubMedGoogle Scholar
  209. 203.
    Quesada JR, Hersh EM, Rueben J et al. Alpha interferon for induction of remission in hairy cell leukemia. N Engl J Med 1984; 310: 15–18.PubMedGoogle Scholar
  210. 204.
    Quesada JR, Itri L, Gutterman JG. Alpha interferons in hairy cell leukemia (HCL). A five year follow up in 100 patients. J Interf Res 1987; 7: 678.Google Scholar
  211. 205.
    Raefsky EL, Platanias LC, Zoumbos NC et al. Studies of interferon as a regulator of hematopoietic cell proliferation. J Immunol 1985; 135: 2507.Google Scholar
  212. 206.
    Ravdin PM, Borden EC, Magers CF et al. Interferon alfa-N1 and continuous infusion vinblastine for treatment of advanced renal cell carcinoma. J Biol Resp Mod 1990; 9: 108–11.Google Scholar
  213. 207.
    Real FX, Oettgen HF, Krown SE. Kaposi’s sarcoma and the acquired immunodeficiency syndrome. Treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol 1986; 4: 544–51.PubMedGoogle Scholar
  214. 208.
    Revel M, Kimch A, Shulman L. Role of interferon-induced enzymes in the antiviral and antimitogenic effects of interferon. Ann NY Acad Sci 1980; 350: 459–73.PubMedGoogle Scholar
  215. 209.
    Rohatiner A, Crowther D, Redford J et al. The role of interferon in follicular lymphoma. Proc Am Soc Clin Oncol 1996; 15: 418.Google Scholar
  216. 210.
    Rohatiner A, Price CGA, Steward W et al. A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphom. Br J Cancer 2001, 85: 29.PubMedCentralPubMedGoogle Scholar
  217. 211.
    Rohatiner AZS et al. Proc Am Soc Clin Oncol 1998; 17: 11.Google Scholar
  218. 212.
    Rohatiner AZS, Prior PF, Burton AC et al. Central nervous system toxicity of interferon. Br J Cancer 1983; 47: 419–22.PubMedCentralPubMedGoogle Scholar
  219. 213.
    Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alpha-2b. J Clin Oncol 1999; 17: 968–75.PubMedGoogle Scholar
  220. 214.
    Rosenblum MG, Lamki JL, Murana AJ et al. Interferon induced changes in pharmacokinetics and tumor uptake of 111 In-labelledantimelanoma antibody 96.5 in melanoma patients. J Natl Cancer Inst 1988; 80: 160–4.PubMedGoogle Scholar
  221. 215.
    Rosenblum MG, Maxwell BL, Talpaz M et al. In vivo sensitivity and resistance of chronic myelogenous leukemia cells to alpha interferon: correlation with receptor binding and induction of 2’,5’-oligoadenylate synthetase. Cancer Res 1986; 46: 4848–52.PubMedGoogle Scholar
  222. 216.
    Rossi G. Interferon and cell differentiation. In: Gresser I, ed. Interferon, Vol. 6. New York: Academic Press, 1985: 31–68.Google Scholar
  223. 217.
    Rosti G, Bonifazi F, De Vivo A et al. Cytarabine increases karyotypic response in alpha interferon treated chronic myeloid leukemia patients: results of a national prospective randomized trial of the Italian Cooperative Study Group on CML. Blood 1999; 94: 600A.Google Scholar
  224. 218.
    Rozman C, Montserrat E, Vinolas N et al. Recombinant alpha2 interferon in the treatment of B chronic lymphocytic leukemia in early stages. Blood 1988; 71: 1295–8.PubMedGoogle Scholar
  225. 219.
    Rupoli S, Barulli S, Guiducci B et al. Low dose interferonalpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous -T Cell Lymphoma Multicenter Study Group. Haematologica. 1999; 84: 809–13.PubMedGoogle Scholar
  226. 220.
    Salmon SE, Crowley JJ, Grogan TM et al. Combination chemotherapy, glucocorticosteroids, and interferon alfa in the treatment of multiple myeloma. A Southwest Oncology Group Study. J Clin Oncol 1994; 12: 2405–14.PubMedGoogle Scholar
  227. 221.
    Scheithauer W, Cortelezzi A, Fritz E et al. Combined alpha-2C-interferon/VMCP polychemotherapy versus VMCP as induction therapy in multiple myeloma: a prospective randomized trial. J Biol Resp Modif 1989; 8: 109–15.Google Scholar
  228. 222.
    Schofield JR, Robinson WA, Murphy JR et al. Low doses of interferon-a are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med 1994; 121: 736–44.PubMedGoogle Scholar
  229. 223.
    Schornagel JH, Verweij J, Ten Bokkel Huinink WV et al. Phase II study of recombinant interferon alpha-A and vinblastine in advanced renal cell carcinoma. J Urol 1989; 142: 253–4.PubMedGoogle Scholar
  230. 224.
    Schulof RS, Lloyd MJ, Sallings JJ et al. Recombinant leukocyte A interferon in B-cell chronic lymphocyticGoogle Scholar
  231. leukemia: in vivo effects on autologous antitumor immunity. J Biol Resp Modif 1985; 4: 310–23.Google Scholar
  232. 225.
    Senn CC. Biochemical pathways in interferon action. Pharmacol Ther 1984; 24: 235–57.Google Scholar
  233. 226.
    Sertoli MR, Brunette I, Ardizzoui A et al. Recombinant alpha-20 interferon plus vinblastine in the treatment of metastatic renal cell carcinoma. Am J Clin Oncol 1989; 12: 43–5.PubMedGoogle Scholar
  234. 227.
    Shepherd FA, Beaulieu R, Gelmon K. Prospective randomised trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi’s sarcoma associated with human immunodeficiency virus infection: a Canadian HIV clinical trials network study. J Clin Oncol 1998; 16: 1736–42.PubMedGoogle Scholar
  235. 228.
    Shin DM, Khuri FR, Murphy B et al. Combined interferon-alpha, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 2001; 19: 3010–17.PubMedGoogle Scholar
  236. 229.
    Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor-and lymphocyte-induced vascular responses. Cancer Res 1987; 47: 51–5.Google Scholar
  237. 230.
    Sigaux F, Castaigne S, Lehn P et al. Alpha-interferon in hairy cell leukaemia: direct effects on hairy cells or indirect cytotoxicity. Int J Cancer 1987; (Suppl.)1: 2–8.Google Scholar
  238. 231.
    Silver HKB, Connors JM, Salinas FA. Prospectively randomized toxicity study of high-dose versus low-dose treatment strategies for lymphoblastoid interferon. Cancer Treat Rep 1985; 69: 743–50.PubMedGoogle Scholar
  239. 232.
    Silver RT. Interferon-alpha 2b: a new treatment for polycythemia vera. Ann Intern Med 1993; 119: 1091–2.PubMedGoogle Scholar
  240. 233.
    Silver RT, Coleman M, Benn P et al. Interferon (rIFN) alfa 2b has activity in treating chronic myeloid leukemia (CML) in rIFN gamma failures. Proc Am Soc Clin Oncol 1987; 6: 149 (abstract).Google Scholar
  241. 234.
    Singh RK, Gutman M, Bucana CD et al. Interferons alpha and beta downregulate the expression of basic fibroblast growth factor in human carcinoma. Proc Natl Acad Sci.USA 1995; 92: 4562.PubMedGoogle Scholar
  242. 235.
    Smalley RV, Andersen JW, Hawkins J et al. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin’s lymphoma–an ECOG study. New Engl J Med 1992; 327: 1336–41.PubMedGoogle Scholar
  243. 236.
    Smalley RV, Anderson SS, Tuttle RL et al. A randomized comparison of a low dose and a standard dose of alpha interferon (Wellferon®) in hairy cell leukemia. Blood 1991; 78: 3133–41.PubMedGoogle Scholar
  244. 237.
    Smalley RV, Connors J, Tuttle RL et al. Splenectomy vs. alpha interferon: a randomized study in patients with previously untreated hairy cell leukemia. Am J Hematol 1992; 41: 13–18.PubMedGoogle Scholar
  245. 238.
    Smalley RV, Vogel J, Huguley CM Jr et al. Chronic granulocytic leukemia: cytogenetic conversion of the bone marrow with cycle-specific chemotherapy. Blood 1977; 50: 107–13.PubMedGoogle Scholar
  246. 239.
    Smedley HM, Wheeler T. Toxicity of IFN. In: Sikora K, ed. Interferon and Cancer. New York: Plenum, 1983: 203–10.Google Scholar
  247. 240.
    Solal-Celigy P, Lepage E, Brousse N et al. Doxorubicincontaining regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d’Etude des Lymphomes Folliculaires. J Clin Oncol 1998; 16: 2332–8.Google Scholar
  248. 241.
    Spinna CA, Dahey JL, Durhos-Smith D et al. Suppression of NK cell cytotoxicity in the peripheral blood of patients receiving interferon therapy. J Biol Resp Modif 1983; 2: 458–9.Google Scholar
  249. 242.
    Stadler R, Otte HG, Luger T et al. Prospective randomized multicenter clinical trial on the use of interferon-2a plusGoogle Scholar
  250. acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998; 92: 3578–81.Google Scholar
  251. 243.
    Stadler WM, Kuzel TM, Raghaven D et al. Metastatic bladder cancer: advances in treatment. Eur J Cancer 1997; 33: 23.Google Scholar
  252. 244.
    Steis RG, Smith JW, Urba WJ et al. Resistance to recombinant interferon alfa 2a in hairy cell leukemia associated with neutralizing anti-interferon antibodies N Engl J Med 1988; 318: 1409–13.Google Scholar
  253. 245.
    Steis RG, Urba WJ, Clark JW et al. Immunogenicity of different types of interferons in the treatment of hairy-cell leukemia. N Engl J Med 1988; 319: 1227.Google Scholar
  254. 246.
    Stewart WE, Blanchard DK. Interferons, cytostatic and immunomodulatory effects. In: Immunity to Cancer. New York: Academic Press, 1985: 295–307.Google Scholar
  255. 247.
    Strander H, Abramson U, Aparisi T. Adjuvant interferon treatment of human osteosarcoma. Rec Results Cancer Res 1978; 68: 40.Google Scholar
  256. 248.
    Strander H, Cantell K, Inginarison S et al. Interferon treatment of osteogenic sarcoma: a clinical trial. In: Conference on Modulation of Host Immune Resistance in the Prevention and Treatment of Induced Neoplasms. Washington, DC, US Government Printing Office, 1980: 377–381.Google Scholar
  257. 249.
    Talpaz M, Kantarjian HM, McCredie K et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986; 314: 1065–9.PubMedGoogle Scholar
  258. 250.
    Talpaz M, Kantarjian HM, McCredie KB et al. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 1987; 69: 1280–8.PubMedGoogle Scholar
  259. 251.
    Talpaz M, Kurzrock R, Kantarjian H et al. Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis. Am J Med 1989; 86: 554–8.PubMedGoogle Scholar
  260. 252.
    Talpaz M, McCredie KB, Mavligit GM et al. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983; 62: 689–92.PubMedGoogle Scholar
  261. 253.
    Talpaz M, Trujillo JM, Mittelman WN et al. Suppression of clonal evolution in two chronic myelogenous leukemia patients treated with leukocyte interferon. Br J Haematol 1985; 60: 619–24.PubMedGoogle Scholar
  262. 254.
    Taniguchi T, Ohno S, Fujii-Kuriyama Yet al. The nucleotide sequence of human fibroblast interferon cDNA. Gene 1980; 20: 11–15.Google Scholar
  263. 255.
    Taylor-Papadimitriou J, Ebsworth N, Rozengurt E. Possible mechanisms of interferon-induced growth inhibition. In: Ford, RJ, ed. Mediators in Cell Growth and Differentiation. New York: Raven Press, 1985: 283–298.Google Scholar
  264. 256.
    The Myeloma Trialists’ Collaborative Group. Interferon as therapy for multiple myeloma; an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001; 113: 1020–34.Google Scholar
  265. 257.
    Tichelli A, Gratwohl A, Berger C et al. Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2a. Blut 1989; 58: 15–19.PubMedGoogle Scholar
  266. 258.
    Toy J. The interferons. Clin Exp Immunol 1983; 54: 1–13.PubMedCentralPubMedGoogle Scholar
  267. 259.
    Trinchieri G, Perussia B. Immune interferon: a pleiotropic lymphokine with multiple effects. Immunol Today 1985; 6: 131–6.Google Scholar
  268. 260.
    Trump DL, Elson P, Proper TK et al. Randomized controlled trial of adjuvant therapy with lymphoblastoid interferon in resected high risk renal cell carcinoma. Proc Am Soc Clin Oncol 1996; 15: 253.Google Scholar
  269. 261.
    Tura S, for the Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa 2a as compared with conventional chemotherapy for the treatmentGoogle Scholar
  270. of chronic myeloid leukemia. N Engl J Med 1994; 330: 820–5.Google Scholar
  271. 262.
    Uze G, Lutfalla G, Gresser I. Genetic transfer of a functional human interferon-a receptor into mouse cells: cloning and expression of its cDNA. Cell 1990; 60: 225–34.PubMedGoogle Scholar
  272. 263.
    VanderMolen LA, Steis RG, Duffey PL et al. Low versus high-dose interferon alpha 2a in relapsed indolent non-Hodgkin’s lymphoma. J Natl Cancer Inst 1990; 82: 235–8.PubMedGoogle Scholar
  273. 264.
    Varesio L, Blasi E, Thurman G et al. Recombinant IFNgamma activates macrophages to become tumoricidal. Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute, and Preclinical Screening Program. NCI-FCRF, Frederick, MD, 1985.Google Scholar
  274. 265.
    Vilcek J, Kelke HC, Jumming LE et al. Structure and function of human interferon gamma. In: Ford RJ, ed. Mediators in Cell Growth and Differentiation. New York: Raven Press, 1985: 299–313.Google Scholar
  275. 266.
    Volberding P, Valero R, Rothman J et al. Alpha interferon therapy of Kaposi’s sarcoma in AIDS. Ann NY Acad Sci 1984; 437: 439–47.PubMedGoogle Scholar
  276. 267.
    von Wussow P, Frund M, Dahle S et al. Immunogenicity of different types of interferons in the treatment of hairy cell leukemia. N Engl J Med 1988; 319: 1226.PubMedGoogle Scholar
  277. 268.
    von Wussow P, Hehlmann R, Hochhaus T et al. Roferon (rIFN-a2a) is more immunogenic than intron A (rIFNa2b) in patients with chronic myelogenous leukemia. J Interferon Res 1994; 14: 217–19.PubMedGoogle Scholar
  278. 269.
    Vugrin D, Hood L, Laszlo J. A phase II trial of high-dose human lymphoblastoid alpha interferon in patients with advanced renal carcinoma. Cancer Treat Rep 1985; 69: 817–20.PubMedGoogle Scholar
  279. 270.
    Wadler S, Schwartz EL, Goldman M et al. 5-Fluorouracil and recombinant alpha-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1769–75.PubMedGoogle Scholar
  280. 271.
    Wadler S, Wiernik PH. Clinical update on the role of fiuorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma. Semin Oncol 1990; 17 (Suppl. 1): 16–21.PubMedGoogle Scholar
  281. 272.
    Wagstaff J, Loynds P, Scarffe JH. A phase II study of rDNA human alpha 2 interferon in multiple myeloma. Cancer Treat Rep 1985; 69: 495–8.PubMedGoogle Scholar
  282. 273.
    Weiner LM, Moldofsky PJ, Gatenby RA et al. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma interferon and the murine monoclo-Google Scholar
  283. nal antibody CO-17–1-A in advanced colorectal carcinoma. Cancer Res 1988; 49: 1609–21.Google Scholar
  284. 274.
    Weiss GR, Liu PY, Alberts DS et al. 13-Cis-retinoic acid or all-trans-retinoic acid plus interferon-alpha in recurrent cervical cancer: a Southwest Oncology Group phase II randomized trial. Gynecol Oncol 1998; 71: 386–90.PubMedGoogle Scholar
  285. 275.
    Westin J, Ro~djer S, Turesson I et al. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma. A randomized study. Br J Haematol 1995; 89: 561–8.PubMedGoogle Scholar
  286. 276.
    Wiernik PH, Schwartz B, Dutcher JP et al. Successful treatment of hairy cell leukemia with beta ser interferon. Am J Hematol 1990; 33: 244–8.PubMedGoogle Scholar
  287. 277.
    Wirth MP. Immunotherapy for metastatic renal cell carcinoma Urol Clin N Am 1993; 20: 283–95.Google Scholar
  288. 278.
    Wisloff F, Gulbrandsen N. Health-related quality of life and patient’s perceptions in interferon-treated multiple myeloma patients. Nordic Myeloma Study Group. Acta Oncol 2000; 39: 809–13.Google Scholar
  289. 279.
    Wollina U, Looks A, Meyer J et al. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial. J Am Acad Dermatol 2001; 44: 253–60.PubMedGoogle Scholar
  290. 280.
    Worman CP, Catovsky D, Cawley JC et al. The UK experience with human lymphoblastoid interferon in HCL: a report of the first 50 cases. Leukemia 1987; 1: 320–2.PubMedGoogle Scholar
  291. 281.
    Worman CP, Nethersell ABW, Bottomley JM et al. Natural IFN-a therapy in hairy-cell leukaemia (Namalva-type IFN-Wellferon). Klin Wochenschr 1987; 65: 685–7.PubMedGoogle Scholar
  292. 282.
    Xu D, Erickson S, Szeps M et al. Interferon alpha down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells. Blood 2000; 96: 4313–8.PubMedGoogle Scholar
  293. 283.
    Yoffe G, Blick M, Kantarjian H et al. Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leukemia. Blood 1987; 69: 961–3.PubMedGoogle Scholar
  294. 284.
    Zinzani PL, Magagnoli M, Bendain M et al. Long term-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. Haematologica 2000; 85: 922–5.PubMedGoogle Scholar
  295. 285.
    Zoon KC, Hu R, Nedden DL et al. Further studies on the purification and partial characterization of human lymphoblastoid interferon alphas. In: Stewart WE II, Schelle-kens H, eds. The Biology of the Interferon System. Amsterdam: Elsevier, 1986: 55–8.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2003

Authors and Affiliations

  • David Goldstein
  • Robert Jones
  • Richard V. Smalley
  • Ernest C. Borden

There are no affiliations available

Personalised recommendations